Skip to content

The Impact of Continuous Infusion of Esketamine on Postoperative Cognitive Function in Elderly Malnourished Patients Undergoing Total Hip Arthroplasty and the Relationship Between Perioperative Gut Microbiota Characteristics and Postoperative Cognitive Dysfunction.

The Impact of Continuous Infusion of Esketamine on Postoperative Cognitive Function in Elderly Malnourished Patients Undergoing Total Hip Arthroplasty and the Relationship Between Perioperative Gut Microbiota Characteristics and Postoperative Cognitive Dysfunction.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106157
Enrollment
Unknown
Registered
2025-07-18
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Cognitive Dysfunction

Interventions

S-ketamine group:0.2mg/kg/h Esketamine
Dexmedetomidine group:0.5ug/kg/h Dexmedetomidine

Sponsors

Guiyang Fourth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age: 60 to 80 years old; 2.American Society of Anesthesiologists (ASA) Physical Status Classification: Class I to III; 3.Body Mass Index (BMI) in kg/m²: 18 to 30; 4.Patients scheduled for unilateral total hip replacement surgery; 5.Meeting the diagnostic criteria for malnutrition according to the Global Leadership Initiative on Malnutrition (GLIM); 6.Preoperative assessment using the Montreal Cognitive Assessment (MOCA) scale: inclusion if the score is 26 or above; 7.Have signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with mental illnesses. 2. Patients at severe risk of elevated blood pressure or intracranial pressure. 3. Patients with high intraocular pressure, glaucoma, or penetrating eye trauma. 4. Patients with poorly controlled or untreated hypertension, with resting systolic/diastolic blood pressure exceeding 180/110 mmHg. 5. Patients with untreated or inadequately treated hyperthyroidism. 6. Patients allergic to ketamine, propofol, or opioids. 7. Patients with unstable ischemic heart disease. 8. Individuals with combined heart failure (NYHA heart function classification >= Grade 3), history of stroke, severe liver disease (such as liver failure), or chronic renal failure (glomerular filtration rate < 30 mL/min). 9. Preoperative patients with Parkinson's disease and/or Alzheimer's disease, combined with anxiety, depression, and emotional disorders. 10. Individuals with a history of cerebrovascular accidents or long-term use of medications affecting the nervous and psychiatric systems. 11. Those who have participated in other trials.

Design outcomes

Primary

MeasureTime frame
The incidence of POCD within 3 days after surgery.;The types and quantities of intestinal flora in patients before surgery (1 day prior) and after the first postoperative bowel movement.;

Secondary

MeasureTime frame
Numeric Rating Scale (NRS).;Anesthesia time;The incidence of postoperative nausea and vomiting (PONV).;Antibiotic type and dosage;Psychiatric symptoms within 3 days after surgery;Surgery time;Recovery room stay time;

Countries

China

Contacts

Public ContactQianglin Yi

Guiyang Fourth People’s Hospital

yiqianglin2021@163.com+86 135 9505 6784

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026